Alice Nettleton
Stock Analyst at UBS
(1.61)
# 3,752
Out of 5,090 analysts
14
Total ratings
37.5%
Success rate
0.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alice Nettleton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ODTX Odyssey Therapeutics | Maintained: Buy | $27 | $18.99 | +42.18% | 2 | Oct 21, 2026 | |
| ABCL AbCellera Biologics | Initiated Coverage: Buy | $18 | $11.71 | +53.71% | 1 | Oct 12, 2026 | |
| BIOA BioAge Labs | Initiated Coverage: Hold | $8 | $5.56 | +43.88% | 1 | Oct 12, 2026 | |
| EVMN Evommune | Initiated Coverage: Hold | $8 | $5.38 | +48.70% | 1 | Oct 12, 2026 | |
| GLUE Monte Rosa Therapeutics | Initiated Coverage: Buy | $19 | $11.36 | +67.25% | 1 | Oct 12, 2026 | |
| KARD Kardigan | Initiated Coverage: Buy | $25 | $13.51 | +85.05% | 1 | Oct 12, 2026 | |
| MLYS Mineralys Therapeutics | Initiated Coverage: Hold | $29 | $21.58 | +34.38% | 1 | Oct 12, 2026 | |
| NKTR Nektar Therapeutics | Initiated Coverage: Hold | $53 | $39.22 | +35.14% | 1 | Oct 12, 2026 | |
| OCUL Ocular Therapeutix | Initiated Coverage: Buy | $14 | $6.65 | +110.53% | 1 | Oct 12, 2026 | |
| PTGX Protagonist Therapeutics | Initiated Coverage: Buy | $184 | $137.99 | +33.34% | 1 | Oct 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $17 | $5.84 | +191.10% | 1 | Oct 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $120 | $91.40 | +31.29% | 1 | Oct 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $26 | $21.83 | +19.13% | 1 | Oct 12, 2026 |
Odyssey Therapeutics
Oct 21, 2026
Maintained: Buy
Price Target: $27
Current: $18.99
Upside: +42.18%
AbCellera Biologics
Oct 12, 2026
Initiated Coverage: Buy
Price Target: $18
Current: $11.71
Upside: +53.71%
BioAge Labs
Oct 12, 2026
Initiated Coverage: Hold
Price Target: $8
Current: $5.56
Upside: +43.88%
Evommune
Oct 12, 2026
Initiated Coverage: Hold
Price Target: $8
Current: $5.38
Upside: +48.70%
Monte Rosa Therapeutics
Oct 12, 2026
Initiated Coverage: Buy
Price Target: $19
Current: $11.36
Upside: +67.25%
Kardigan
Oct 12, 2026
Initiated Coverage: Buy
Price Target: $25
Current: $13.51
Upside: +85.05%
Mineralys Therapeutics
Oct 12, 2026
Initiated Coverage: Hold
Price Target: $29
Current: $21.58
Upside: +34.38%
Nektar Therapeutics
Oct 12, 2026
Initiated Coverage: Hold
Price Target: $53
Current: $39.22
Upside: +35.14%
Ocular Therapeutix
Oct 12, 2026
Initiated Coverage: Buy
Price Target: $14
Current: $6.65
Upside: +110.53%
Protagonist Therapeutics
Oct 12, 2026
Initiated Coverage: Buy
Price Target: $184
Current: $137.99
Upside: +33.34%
Oct 12, 2026
Initiated Coverage: Buy
Price Target: $17
Current: $5.84
Upside: +191.10%
Oct 12, 2026
Initiated Coverage: Buy
Price Target: $120
Current: $91.40
Upside: +31.29%
Oct 12, 2026
Initiated Coverage: Hold
Price Target: $26
Current: $21.83
Upside: +19.13%